Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IMM167
MIFTS: 78

Immune Deficiency Disease

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Immune Deficiency Disease

About this section

MalaCards integrated aliases for Immune Deficiency Disease:

Name: Immune Deficiency Disease 57 29 71
Immunodeficiency 29 54 6 39
Primary Immunodeficiency Disease 12 36 15
Primary Immunodeficiency 58 29 6
Immunologic Deficiency Syndromes 44 71
Primary Immune Deficiency Disorder 71
Immune Deficiency Disorder 12
Immunodeficiency Syndrome 12
Immune System Diseases 71
Immune Disorder 54
Hypoimmunity 12

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal recessive


HPO:

31
immune deficiency disease:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare immunological diseases


External Ids:

Disease Ontology 12 DOID:612
OMIM® 57 242850
KEGG 36 H01725
ICD9CM 34 279.3
MeSH 44 D007153
NCIt 50 C39725
SNOMED-CT 67 191005003
UMLS via Orphanet 72 C0398686
Orphanet 58 ORPHA101997
MedGen 41 C1855771
UMLS 71 C0021051 C0021053 C0398686 more
Sources

Summaries for Immune Deficiency Disease

About this section
KEGG : 36 Primary immunodeficiency diseases (PIDs) are genetically determined disorders of the immune system resulting in greatly enhanced susceptibility to infectious disease, autoimmunity and malignancy. Many are associated with single gene defects, whereas others may be polygenic or may represent interactions of genetically determined characteristics with environmental or infectious stresses. There are more than 150 different disorders which have been described till date. PIDs are broadly classified as disorders of adaptive immunity (i.e., T-cell, B-cell or combined immunodeficiencies) or of innate immunity (e.g., phagocyte and complement disorders). Early diagnosis and treatment are imperative for preventing significant disease-associated morbidity.

MalaCards based summary : Immune Deficiency Disease, also known as immunodeficiency, is related to immunodeficiency 41 with lymphoproliferation and autoimmunity and immunodysregulation, polyendocrinopathy, and enteropathy, x-linked, and has symptoms including pathological conditions, signs and symptoms An important gene associated with Immune Deficiency Disease is RAG2 (Recombination Activating 2), and among its related pathways/superpathways are Primary immunodeficiency and Innate Immune System. The drugs Amphotericin B and Morphine have been mentioned in the context of this disorder. Affiliated tissues include t cells, liver and bone, and related phenotypes are cellular immunodeficiency and decreased circulating total igm

Disease Ontology : 12 An immune system disease that results when one or more essential parts of the immune system is missing or not working properly at birth due to a genetic mutation.

Wikipedia : 74 Immunodeficiency, also known as immunocompromisation, is a state in which the immune system's ability to... more...

More information from OMIM: 242850
Sources

Related Diseases for Immune Deficiency Disease

About this section

Diseases related to Immune Deficiency Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2692)
# Related Disease Score Top Affiliating Genes
1 immunodeficiency 41 with lymphoproliferation and autoimmunity 33.2 IL2RA IL2 CD4
2 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 33.2 IL4 IL2RA IL2 IL10 CD4
3 immunodeficiency 63 with lymphoproliferation and autoimmunity 33.0 IL2RA IL2
4 jak3-deficient severe combined immunodeficiency 32.8 IL4 IL2
5 t cell deficiency 32.6 RAG2 IL2 CD4
6 oral hairy leukoplakia 32.4 ITIH4 IL10 CD4
7 toxoplasmosis 32.4 IL4 IL10 CD79A CD40LG CCR5
8 immune system disease 32.3 IL4 IL2 IL10 CD4
9 human immunodeficiency virus infectious disease 32.1 ITIH4 IL4 IL2RA IL2 IL10 CD79A
10 pneumocystosis 32.1 IL2 CD40LG CD4 CCR5
11 cryptococcosis 32.1 IL4 IL10 CD4
12 chickenpox 32.0 IL4 IL2 IL10 CD4
13 lymphoma, non-hodgkin, familial 31.9 SYK IL2RA IL2 CD79A CD4 ATM
14 progressive multifocal leukoencephalopathy 31.9 IL2 CD40LG CD4
15 exanthem 31.9 SYK IL2 IL10 CD4
16 common variable immunodeficiency 31.9 RAG2 RAC2 IL4 IL2RA IL2 IL10
17 cryptosporidiosis 31.9 CD79A CD40LG CD4
18 leishmaniasis 31.9 IL4 IL2 IL10 IFNGR1
19 herpes zoster 31.8 IL2 IL10 CD4 CCR5
20 myocarditis 31.8 IL4 IL2 IL10 CD40LG
21 uveitis 31.8 IL4 IL2RA IL2 IL10 CCR5
22 visceral leishmaniasis 31.8 IL4 IL2RA IL2 IL10 IFNGR1
23 syphilis 31.8 CD79A CD40LG CD4 CCR5
24 malaria 31.7 IL4 IL2RA IL2 IL10 IFNGR1 CD40LG
25 fungal infectious disease 31.7 SYK IL4 IL2 IL10 CD4
26 pulmonary tuberculosis 31.6 IL4 IL2RA IL2 IL10 IFNGR1
27 autoimmune lymphoproliferative syndrome 31.6 RIPK1 IL2RA IL2 IL10 CD4
28 severe combined immunodeficiency 31.6 RAG2 RAC2 MYOC MYH7 IL4 IL2RA
29 meningoencephalitis 31.6 IL10 CD79A CD40LG CD4
30 combined immunodeficiency 31.6 RAG2 RAC2 MYOC MYH7 IL4 IL2RA
31 chagas disease 31.6 IL4 IL2 IL10 CD4 CCR5
32 cholangitis 31.5 IL2 IL10 CCR5
33 systemic lupus erythematosus 31.5 SYK IL4 IL2RA IL2 IL10 CD79A
34 chorioretinitis 31.5 IL2 IL10 CD4
35 acquired immunodeficiency syndrome 31.5 ITIH4 IL2RA IL2 IL10 CD79A CD40LG
36 toxic shock syndrome 31.5 IL4 IL2 IL10 CD40LG
37 lymphadenitis 31.5 IL2RA IL10 IFNGR1 CD4
38 purpura 31.5 IL4 IL10 CD79A
39 agammaglobulinemia, x-linked 31.5 SYK CD79A CD40LG CD4
40 b cell deficiency 31.5 IL4 IL2 IL10 CD40LG CD4
41 hypereosinophilic syndrome 31.4 IL4 IL2RA IL2 IL10
42 colitis 31.4 SYK IL4 IL2 IL10 CD4
43 omenn syndrome 31.4 RAG2 IL4 IL10 IFNGR1 CD40LG CD4
44 asthma 31.4 SYK IL4 IL2RA IL2 IL10 CD79A
45 sclerosing cholangitis 31.4 IL2 IL10 CCR5
46 leukemia, chronic lymphocytic 31.4 SYK IL4 IL2RA IL2 IL10 CD79A
47 lymphopenia 31.4 RAC2 MYOC MYH7 IL4 IL2RA IL2
48 strongyloidiasis 31.4 IL4 CD79A CD4
49 stomatitis 31.4 IL4 IL2 IL10 CD4
50 immunodeficiency with hyper-igm, type 1 31.4 RAG2 IL4 CD79A CD40LG CD4

Comorbidity relations with Immune Deficiency Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bronchitis
Deficiency Anemia Heart Disease
Neutropenia Rheumatoid Arthritis

Graphical network of the top 20 diseases related to Immune Deficiency Disease:



Diseases related to Immune Deficiency Disease
Sources

Symptoms & Phenotypes for Immune Deficiency Disease

About this section

Human phenotypes related to Immune Deficiency Disease:

31 (show all 7)
# Description HPO Frequency HPO Source Accession
1 cellular immunodeficiency 31 HP:0005374
2 decreased circulating total igm 31 HP:0002850
3 recurrent bacterial infections 31 HP:0002718
4 recurrent viral infections 31 HP:0004429
5 fulminant hepatitis 31 HP:0004787
6 cholangitis 31 HP:0030151
7 humoral immunodeficiency 31 HP:0005363

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
G I:
fulminant hepatitis
intrahepatic sclerosing cholangitis

Misc:
susceptibility to both bacterial and viral infections
septicemia common

Immunology:
partial humoral immunodeficiency
partial cellular immunodeficiency
severe igm deficiency
primary immunization antibody response defective

Clinical features from OMIM®:

242850 (Updated 05-Mar-2021)

UMLS symptoms related to Immune Deficiency Disease:


pathological conditions, signs and symptoms

GenomeRNAi Phenotypes related to Immune Deficiency Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after gemcitabine stimulation GR00107-A-2 8.8 ATM RIPK1 SYK

MGI Mouse Phenotypes related to Immune Deficiency Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 ATM CCR5 CD4 CD40LG CD79A GIMAP6
2 hematopoietic system MP:0005397 10.31 ATM CCR5 CD4 CD40LG CD79A GIMAP6
3 homeostasis/metabolism MP:0005376 10.3 ATM CCR5 CD4 CD40LG CD79A GIMAP6
4 cardiovascular system MP:0005385 10.27 ATM CCR5 CD40LG GIMAP6 IFNGR1 IL10
5 immune system MP:0005387 10.22 ATM CCR5 CD4 CD40LG CD79A GIMAP6
6 endocrine/exocrine gland MP:0005379 10.21 ATM CD4 CD40LG IFNGR1 IL10 IL2
7 digestive/alimentary MP:0005381 10.11 CCR5 CD4 IFNGR1 IL10 IL2 IL2RA
8 mortality/aging MP:0010768 10.06 ATM CCR5 CD4 CD40LG CD79A IFNGR1
9 liver/biliary system MP:0005370 10.03 CCR5 CD79A IFNGR1 IL10 IL2 IL4
10 neoplasm MP:0002006 9.56 ATM CCR5 CD79A IFNGR1 IL10 IL2
11 no phenotypic analysis MP:0003012 9.23 CD4 CD79A IL10 IL2 IL4 MYH7
Sources

Drugs & Therapeutics for Immune Deficiency Disease

About this section

Drugs for Immune Deficiency Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 581)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
2
Morphine Approved, Investigational Phase 4 57-27-2 5288826
3
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
4
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
5
Sulfamethoxazole Approved Phase 4 723-46-6 5329
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Aminosalicylic Acid Approved Phase 4 65-49-6 4649
8
Fluconazole Approved, Investigational Phase 4 86386-73-4 3365
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Zidovudine Approved Phase 4 30516-87-1 35370
11
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
12
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787
13
Fosamprenavir Approved Phase 4 226700-79-4 131536
14
Methadone Approved Phase 4 76-99-3 4095
15
Ribavirin Approved Phase 4 36791-04-5 37542
16
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
17
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
18
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
20
Sorbitol Approved Phase 4 50-70-4 5780
21
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173 46783403
22
Cytarabine Approved, Investigational Phase 4 147-94-4 6253
23
Vincristine Approved, Investigational Phase 4 2068-78-2, 57-22-7 5978
24
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
25
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
26
carbamide peroxide Approved Phase 4 124-43-6
27
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
28
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
29
Nevirapine Approved Phase 4 129618-40-2 4463
30
Nicotine Approved Phase 4 54-11-5 942 89594
31
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
32
Azithromycin Approved Phase 4 83905-01-5 55185 447043
33
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
34
Cobicistat Approved Phase 4 1004316-88-4
35
Rilpivirine Approved Phase 4 500287-72-9 6451164
36
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
37
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
38
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
39
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
40
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
42
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
43
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
44 Liposomal amphotericin B Phase 4
45 Vitamin B Complex Phase 4
46 Folic Acid Antagonists Phase 4
47 Neuroprotective Agents Phase 4
48 Antimetabolites Phase 4
49 Vitamin B9 Phase 4
50 Folate Phase 4

Interventional clinical trials:

(show top 50) (show all 2152)
# Name Status NCT ID Phase Drugs
1 Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach Unknown status NCT01875952 Phase 4 Isoniazid
2 Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders Unknown status NCT02490956 Phase 4
3 Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
4 A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
5 Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial). Unknown status NCT02337322 Phase 4 Dolutegravir;Darunavir/r
6 Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
7 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
8 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
9 Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status. Unknown status NCT02135055 Phase 4 Midazolam;Morphine
10 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
11 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
12 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
13 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
14 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
15 Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B Unknown status NCT03120494 Phase 4 Emtricitabine and Tenofovir
16 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
17 A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents Completed NCT01289847 Phase 4
18 Evaluation of the Efficacy and Safety of Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] for Replacement Therapy in Pediatric Subjects With Primary Immunodeficiency Diseases. Completed NCT00634569 Phase 4
19 Mesalamine to Reduce T Cell Activation in HIV Infection Completed NCT01090102 Phase 4 Mesalamine (5-aminosalicylic acid, Apriso);Placebo
20 Assessment of the IgG Trough Level in Subjects With Primary Immunodeficiency Switching From Standard Subcutaneous Immunoglobulin (SCIG) to Every Other Week HyQvia Completed NCT02881437 Phase 4 IgHy10
21 An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX®-C in Pediatric Subjects With Primary Immunodeficiency Completed NCT01465958 Phase 4
22 An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency Completed NCT03033745 Phase 4 IgPro20
23 A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push. Completed NCT02180763 Phase 4
24 A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push Completed NCT02503293 Phase 4
25 A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID) Completed NCT00520494 Phase 4 Vivaglobin
26 An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1. Completed NCT00144157 Phase 4 Nevirapine;Zidovudine;3TC
27 Fluconazole Prophylaxis of Thrush in AIDS Completed NCT00001542 Phase 4 fluconazole
28 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
29 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
30 A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa. Completed NCT02348177 Phase 4 lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
31 A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C Completed NCT02881762 Phase 4 Maraviroc
32 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
33 Prospective Epidemiological Study of the Prevalence of HLAB*5701 in HIV-1 Infected Patients Completed NCT00441688 Phase 4 GI265235
34 Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation Completed NCT03314064 Phase 4 Dolutegravir 50 mg
35 A Randomised Controlled Clinical Trial of the Efficacy of HAART Intensification With Maraviroc in HIV Virally Suppressed Patients With Cognitive Impairment Completed NCT01449006 Phase 4 Maraviroc
36 Omacor; Omega-3-Acid Ethyl Ester 90 (n-3 PUFA) and Risk Factors in HIV Infected Patients Treated With HAART, With Special Focus on Lipids Completed NCT00296153 Phase 4 Omega-3-acid ethyl esters 90
37 An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etravirine (ETR) in Combination With Other Antiretrovirals (ARVs) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Completed NCT01422330 Phase 4 Etravirine
38 A Randomised, Open-label, 96-week Study Comparing the Safety and Efficacy of Three Different Combination Antiretroviral Regimens as Initial Therapy for HIV Infection. Completed NCT00335322 Phase 4 Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz);Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV);Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
39 A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry®-Containing Regimen, Switching Them to Once-daily Selzentry® (600mg qd) Plus the Same 2 NRTIs Previously Administered Completed NCT01866267 Phase 4 Maraviroc
40 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
41 The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients Completed NCT02234492 Phase 4 Rosuvastatin
42 Evaluating Performance, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons in Botswana During 2012-2013: The Xpert Package Rollout Evaluation Study (XPRES) Completed NCT02538952 Phase 4
43 A Pilot Study of Daily TDF/FTC-based PrEP Among High-risk Toronto MSM:The PREPARATORY-5 Study Completed NCT02149888 Phase 4 Tenofovir/emtricitabine
44 Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV- Infected Women: An Open Label Trial. Completed NCT01812980 Phase 4
45 Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial Completed NCT01946906 Phase 4 Rifaximin
46 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
47 Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus Completed NCT02761629 Phase 4 Peg-Interferon Alpha-2A;Ribavirin
48 Safety and Immunogenicity of Cervarixâ„¢ in Human Immunodeficiency Virus Infected Females Completed NCT01031069 Phase 4
49 Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial Completed NCT00795717 Phase 4 Lovaza;Placebo
50 Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Completed NCT02711228 Phase 4

Search NIH Clinical Center for Immune Deficiency Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Intramuscular immunoglobulin
varicella-zoster immune globulin
Venoglobulin-I

Cochrane evidence based reviews: immunologic deficiency syndromes

Sources

Genetic Tests for Immune Deficiency Disease

About this section

Genetic tests related to Immune Deficiency Disease:

# Genetic test Affiliating Genes
1 Immune Deficiency Disease 29
2 Immunodeficiency 29
3 Primary Immunodeficiency 29
Sources

Anatomical Context for Immune Deficiency Disease

About this section

MalaCards organs/tissues related to Immune Deficiency Disease:

40
T Cells, Liver, Bone, Bone Marrow, Brain, Lung, Endothelial
Sources

Publications for Immune Deficiency Disease

About this section

Articles related to Immune Deficiency Disease:

(show top 50) (show all 32608)
# Title Authors PMID Year
1
Intrahepatic sclerosing cholangitis associated with a familial immunodeficiency syndrome. 57
4123291 1973
2
Fitness epistasis and constraints on adaptation in a human immunodeficiency virus type 1 protein region. 61 54
20157005 2010
3
Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. 61 54
20439953 2010
4
High viremia is associated with high levels of in vivo major histocompatibility complex class I Downregulation in rhesus macaques infected with simian immunodeficiency virus SIVmac239. 61 54
20219903 2010
5
Subcellular localization of the interaction between the human immunodeficiency virus transactivator Tat and the nucleosome assembly protein 1. 54 61
19888548 2010
6
Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2. 54 61
20015219 2010
7
Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. 61 54
20147395 2010
8
Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells. 54 61
20002211 2010
9
In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. 61 54
20089658 2010
10
A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer. 54 61
20089638 2010
11
Temporal association of large granular lymphocytosis, neutropenia, proviral load, and FasL mRNA in cats with acute feline immunodeficiency virus infection. 54 61
19896217 2010
12
Feline programmed death and its ligand: characterization and changes with feline immunodeficiency virus infection. 61 54
19931185 2010
13
Induction of monocyte chemoattractant protein-1 (MCP-1/CCL2) gene expression by human immunodeficiency virus-1 Tat in human astrocytes is CDK9 dependent. 61 54
20370601 2010
14
Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. 54 61
20347641 2010
15
Computational methods for de novo protein design and its applications to the human immunodeficiency virus 1, purine nucleoside phosphorylase, ubiquitin specific protease 7, and histone demethylases. 54 61
20210752 2010
16
Two siblings with immunodeficiency, facial abnormalities and chromosomal instability without mutation in DNMT3B gene but liability towards malignancy; a new chromatin disorder delineation? 61 54
20211012 2010
17
Blood soluble human leukocyte antigen G levels are associated with human immunodeficiency virus type 1 infection in Beninese commercial sex workers. 54 61
19913587 2010
18
Tuberculosis in children with congenital immunodeficiency syndromes. 61 54
20517730 2010
19
Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection. 54 61
19828602 2010
20
Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. 61 54
19864382 2010
21
Construction and characterization of a new simian/human immunodeficiency viruses clone carrying an env gene derived from a CRF07_BC strain. 61 54
20092794 2009
22
New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. 61 54
19779332 2009
23
Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. 61 54
19776130 2009
24
Generation of a human immunodeficiency virus type 1 chronically infected monkey B cell line expressing low levels of endogenous TRIM5alpha. 61 54
19746418 2009
25
LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. 54 61
19721069 2009
26
Human immunodeficiency virus type 1 (HIV-1) induces the cytoplasmic retention of heterogeneous nuclear ribonucleoprotein A1 by disrupting nuclear import: implications for HIV-1 gene expression. 54 61
19737937 2009
27
A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains. 54 61
19692480 2009
28
Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1. 61 54
19687290 2009
29
Combined immunodeficiency associated with DOCK8 mutations. 61 54
19776401 2009
30
Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphophenia. 61 54
19740990 2009
31
Behavior of non-classical soluble HLA class G antigens in human immunodeficiency virus 1-infected patients before and after HAART: comparison with classical soluble HLA-A, -B, -C antigens and potential role in immune-reconstitution. 61 54
19762282 2009
32
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. 54 61
19651917 2009
33
Enhanced T- and B-cell responses to simian immunodeficiency virus (SIV)agm, SIVmac and human immunodeficiency virus type 1 Gag DNA immunization and identification of novel T-cell epitopes in mice via codon optimization. 54 61
19587137 2009
34
ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication. 61 54
19605474 2009
35
Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes. 54 61
19605470 2009
36
Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer. 54 61
19706714 2009
37
Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. 54 61
19667293 2009
38
Integrase interactor 1 (Ini1/hSNF5) is a repressor of basal human immunodeficiency virus type 1 promoter activity. 54 61
19515827 2009
39
Clinical manifestation of mannose-binding lectin deficiency in adults independent of concomitant immunodeficiency. 54 61
19580835 2009
40
Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques. 54 61
19625392 2009
41
Adenosine deaminase in patients with primary immunodeficiency syndromes: the analysis of serum ADA1 and ADA2 activities. 61 54
19026999 2009
42
Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication. 61 54
19664149 2009
43
Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. 61 54
19553323 2009
44
A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. 61 54
19515760 2009
45
Formation of syncytia is repressed by tetraspanins in human immunodeficiency virus type 1-producing cells. 61 54
19458002 2009
46
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. 54 61
19458010 2009
47
Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype. 54 61
19494007 2009
48
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouse. 54 61
19494021 2009
49
Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. 54 61
19458008 2009
50
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. 54 61
19433561 2009